Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781089 · ClinicalTrials.gov registry record · Phase 4
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
A Phase 4 study of End Stage Renal Disease and Hyperkalemia, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03781089 is a Phase 4 study of End Stage Renal Disease and Hyperkalemia that has completed, run by Duke University. The registered enrollment target is 36 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03781089, a Phase 4 study of End Stage Renal Disease and Hyperkalemia, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether once-daily dosing of patiromer will reduce the frequency of hyperkalemic episodes in ESRD (end stage renal disease) study participants who receive conventional hemodialysis (HD). The study objective is to determine if patiromer administered orally once a day with breakfast or lunch will reduce episodes of hyperkalemia in ESRD study participants who receive thrice-weekly HD.
Conditions Studied
Interventions
- DRUG Patiromer Oral Powder Product
Study Locations (1)
North Carolina
- DaVita Dialysis Sites - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2023-03-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781089
The ClinicalTrials.gov registry entry for NCT03781089 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (96% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Patiromer Oral Powder Product is the first listed.
NCT03781089 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03781089 about?
NCT03781089 is a clinical study titled "Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients". The purpose of this study is to determine whether once-daily dosing of patiromer will reduce the frequency of hyperkalemic episodes in ESRD (end stage renal disease) study participants who receive conventional hemodialysis (HD). The study objective is to determine if patiromer administered orally on...
What is the current status of trial NCT03781089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2019-06-20. Estimated completion is 2023-03-15.
What conditions does trial NCT03781089 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Hyperkalemia.
What interventions are being tested in trial NCT03781089?
The interventions under investigation include: Patiromer Oral Powder Product (DRUG).
Who is sponsoring clinical trial NCT03781089?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03781089 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.